The use of Vivostat PRF® in e.g. wound or orthopaedic procedures is largely dependent on the effect and stability of the PRF®-derived growth factors.

Controlling the release of platelet contents over several days requires not only a delivery media but also protection of the platelets against degradation.

The autologous fibrin matrix in Vivostat PRF® has shown to protect endogenous growth factors against proteolytic degradation and thereby preserve their biological activity.

Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin, Lundquist R. et al., Wound Repair and Regeneration 2008; 16(3): 356-63